The abstract is read at the publisher; the summary is JClub's.
Multicancer early-detection blood testing plus usual care did not reduce stage III or IV cancer incidence across 12 prespecified cancers in a randomized trial in England (incidence rate ratio 1.03).
- Why it matters: It is unclear whether adding blood-based multi-cancer screening to usual care improves detection of advanced disease, leaving a key clinical utility question unanswered.
- What they did: In England, adults aged 50–77 provided blood at up to three annual visits; participants were randomized 1:1 to tested vs stored blood, with stage III/IV incidence compared after three rounds and at least 12 months follow-up.
- The result: Stage III/IV incidence did not differ significantly (incidence rate ratio 1.03; 95% CI 0.92–1.14; P=0.63), and stage IV incidence after 3 rounds was 0.86 (95% CI 0.74–1.00), with fewer than 1% trial-related adverse events and none serious.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.